Spero Therapeutics, Inc.
SPRO
NASDAQ·Healthcare·Biotechnology·Mkt cap $70.1M
$1.21
▼ -0.82%
P/E
-4.17
Mkt Cap
$70.1M
52-Wk Range
$1.08–$3.08
52-Week Range
$1.08 - $3.08
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 39.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-57.1% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying SPRO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 12, 2026
Reported EPS of -$0.16 vs -$0.17 consensus (+5.9% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+5.9%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$258.0K
$0
Margins · last 2Q
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How SPRO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.